News – Page 909 – Endpoints News

Pfizer fronts $250M to nab antisense drug from Akcea/Ionis in up to $1.5B deal

6 years ago

Trio wins Nobel Prize for Medicine for 'fundamental' discovery

6 years ago

Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio

6 years ago

Differin maker Galderma wins FDA approval for a new retinoid for acne

6 years ago

We’ll see this week if the public markets’ love affair with biotech unicorns is still running hot — or not

6 years ago

Antibody research graduates from a top Oxford lab into the biotech world — with $34M to fund R&D work

6 years ago

Ophthalmology biotech upstart is asking investors to bet $85M-plus on their late-stage rival to Restasis and Xiidra

6 years ago

J&J poaches Bayer exec Jim Swanson as chief information officer

6 years ago

Atlas-backed Dyne taps Joshua Brumm as CEO; Sekar Kathiresan woos cardiologist to gene editing startup

6 years ago

Emma Walmsley joins #MeTooPay; Monopar postpones $40M IPO

6 years ago

New NIH viral vector flips the script on sickle cell disease gene therapy

6 years ago

Early functional data on limb girdle patients buoy expectations for Sarepta's gene therapy

6 years ago

King Keytruda: Merck's PD-1 star scores #1 position and $22B+ prediction in another top 10 blockbuster list for 2025

6 years ago

Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program

6 years ago

Book excerpt: How Henri Termeer built Genzyme and pioneered the rare disease industry

6 years ago

Pharma to blame for impeachment woes? Yep, President Trump just suggested that about America's least favorite ...

6 years ago

Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm

6 years ago

NICE fails to endorse Roche's Tecentriq for breast cancer; Elicio closes financing round with $33M

6 years ago

Aeovian Pharmaceuticals brings in $37 million in mTOR play

6 years ago

Regeneron doubles down on partner Adicet's gamma delta T cell tech in $80M financing

6 years ago

Pivotal failure triggers job cuts at San Diego-based Tocagen

6 years ago

Icosavax nabs $51M as synthetic virus heads toward clinic

6 years ago

San Francisco biotech has its heart in heart failure — and $92M in the bank

6 years ago

ARC-T? Alternative CAR-T startup bags $85M for clinical quest to redirect 'blind hunter' T cells

6 years ago

First page Previous page 906 907 908909910 911 912 Next page Last page